Table 2.
Meta-Analysis of Sphingolipids Associated with Emphysema in COPDGene Subjects
| |
Targeted Sphingolipid Platform |
|
Untargeted Metabolomics Platform |
|
Meta-Analysis |
|---|---|---|---|---|---|
| Sphingolipid | β-Slope | P Value | β-Slope | P Value | P Value |
| Ganglioside GM3 (d18:1/16:0) | −0.7654 | 0.0004 | −0.1277 | 0.3768 | 0.0018* |
| Sphingomyelin (d18:0/24:1[15Z]) | −0.4534 | 0.0057 | −0.0623 | 0.5349 | 0.0167* |
| Sphingomyelin (d18:1/14:0) | −0.4335 | 0.0040 | −0.1070 | 0.3650 | 0.0075* |
| Sphingomyelin (d18:1/16:0) | −0.8964 | 0.0010 | −0.1867 | 0.4258 | 0.0037* |
| Sphingomyelin (d18:1/16:1) | −0.5198 | 0.0054 | −0.1459 | 0.3621 | 0.0090* |
| Sphingomyelin (d18:1/24:1[15Z]) | −0.6062 | 0.0009 | −0.2182 | 0.0829 | 0.0004* |
| Sphingomyelin (d18:2/14:0) | −0.3520 | 0.0237 | −0.0673 | 0.5444 | 0.0425 |
The targeted sphingolipid platform included assays for 69 sphingolipids with standards in 129 subjects, and the untargeted metabolomics platform was used for replication using 131 subjects, but it did not include labeled standards (see Reference 34 for more details). The β-slope represents the regression coefficient for emphysema quantitated by high-resolution computed tomography.
*
False discovery rate less than 0.10.